Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab for primary IgA nephropathy
ChiCTR2000036468Phase 4Recruiting
- Sponsor
- Ruijin Hospital
- Start
- Aug 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of rituximab in IgA nephropathy (IgAN) (2 arms), sponsored by Ruijin Hospital. Primary endpoints: Change in proteinuria at 1 year versus baseline, Change in Gd-IgA1 levels and 4 more. Started Aug 2020; status: recruiting.
02
Drugs
rituximab
03
Conditions
IgA nephropathy (IgAN)
Beyond the preview
Go deeper on ChiCTR2000036468.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000036468.